Targeting the vesicular trafficking machinery to control expression of immunomodulatory factors for therapeutic benefit is compelling and is supported by the observation that inhibition of the endosome trafficking regulator neuropilin-2 reduces PD-L1 expression and enables antitumor immune cell activation in prostate cancer cells [63,64]. This evidence concerns the gene CD274 and prostate cancer.